Neutralising antibodies predict protection from severe COVID-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · cited 1× · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · see citing works

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640 · see citing works

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345 · cited 1× · see citing works

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01540-1 · Cited by 1,163 · see citing works

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156 · see citing works

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · see citing works

Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab

Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086 · see citing works

Waning Immunity after the BNT162b2 Vaccine in Israel

Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034 · see citing works

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873 · see citing works

Evidence for antibody as a protective correlate for COVID-19 vaccines

Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · doi:10.1101/2021.03.17.20200246 · Cited by 870 · see citing works

Evidence for antibody as a protective correlate for COVID-19 vaccines

Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.063 · Cited by 870 · see citing works

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

(2021) · doi:10.1101/2021.08.25.21262584 · Cited by 831 · see citing works

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831 · see citing works

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807 · see citing works

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435 · see citing works

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398 · see citing works

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abani, O., Abbas, A. H., Abbas, F., Abbas, M. A., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00163-5 · Cited by 386 · see citing works

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351 · see citing works

Covid-19 Vaccine Effectiveness in New York State

Rosenberg, E., Dorabawila, V., Easton, D., Bauer, U. E., Kumar, J., Hoen, R., Hoefer, D., Wu, M., Lutterloh, E. C., Conroy, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2116063 · Cited by 262 · see citing works

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

Kalimuddin, S., Tham, C. Y. L., Qui, M., de Alwis, R., Sim, J. X. Y., Lim, J. M. E., Tan, H.-C., Syenina, A., Zhang, S. L.-X., Bert, N. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.003 · Cited by 179 · see citing works

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D. G., et al. (2021) · Nature · doi:10.1038/d41586-021-03824-5 · Cited by 177 · see citing works

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce

Keehner, J., Horton, L. E., BINKIN, N. J., Laurent, L. C., Pride, D. T., Longhurst, C., Abeles, S. R., & Torriani, F. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2112981 · Cited by 157 · see citing works

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

Skowronski, D. M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot, D., Prystajecky, N., Tyson, J. R., Gilca, R., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac290 · Cited by 155 · see citing works

Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

(2021) · doi:10.1101/2021.10.26.21265397 · Cited by 153 · see citing works

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 149 · see citing works

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

Khoury, D. S., Schlub, T. E., Cromer, D., Steain, M. C., Fong, Y., Gilbert, P. B., Subbarao, K., Triccas, J. A., Kent, S. J., & Davenport, M. P. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221422 · Cited by 148 · see citing works

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139 · see citing works

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil

Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124 · see citing works

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

Khoury, D. S., Wheatley, A. K., Ramuta, M. D., Reynaldi, A., Cromer, D., Subbarao, K., O’Connor, D. H., Kent, S. J., & Davenport, M. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00471-1 · Cited by 115 · see citing works

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Ranzani, O., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33169-0 · Cited by 111 · see citing works

Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death

Huang, Z., Xu, S., Liu, J., Wu, L., Qiu, J., Wang, N., Ren, J., Li, Z., Guo, X., Tao, F., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02606-8 · Cited by 93 · see citing works

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01262-1 · Cited by 91 · see citing works

Monoclonal antibody levels and protection from COVID-19

Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40204-1 · Cited by 61 · see citing works

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021

Poukka, E., Baum, U., PALMU, A. A. I., Lehtonen, T., Salo, H., Nohynek, H., & Leino, T. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.032 · Cited by 58 · see citing works

A meta-analysis of Early Results to predict Vaccine efficacy against OmicronPreprint

Khoury, D. S., Steain, M. C., Triccas, J. A., Sigal, A., Davenport, M. P., & Cromer, D. (2021) · medRxiv · doi:10.1101/2021.12.13.21267748 · Cited by 51 · see citing works

Early T Cell and Binding Antibody Responses are Associated with COVID-19 RNA Vaccine Efficacy OnsetPreprint

Kalimuddin, S., Tham, C. Y. L., Qui, M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3796533 · Cited by 50 · see citing works

Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis

Stadler, E., Chai, K. L., Schlub, T. E., Cromer, D., Khan, S. R., Polizzotto, M. N., Kent, S. J., Beecher, C., White, H., Turner, T., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00194-5 · Cited by 45 · see citing works

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study

Bianchi, F. P., Tafuri, S., Migliore, G., Vimercati, L., Martinelli, A., Lobifaro, A., Diella, G., Stefanizzi, P., & on behalf of the Control Room Working Group (2021) · Vaccines · doi:10.3390/vaccines9101143 · Cited by 32 · see citing works

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

Kemlin, D., Gemander, N., Depickère, S., Olislagers, V., Georges, D., Waegemans, A., Pannus, P., Lemy, A., Goossens, M. E., Desombere, I., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.02.015 · Cited by 30 · see citing works

Decoupling of omicron variant infections and severe COVID-19

Madhi, S. A., Ihekweazu, C., Rees, H., & Pollard, A. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00109-x · Cited by 21 · see citing works

Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection

(2022) · doi:10.1101/2022.06.05.22275943 · Cited by 12 · see citing works

Monoclonal antibody levels and protection from COVID-19

(2022) · doi:10.1101/2022.11.22.22282199 · Cited by 10 · see citing works

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection

Khan, K., Karim, F., Ganga, Y., Bernstein, M. P., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D. G., Wolter, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32396-9 · Cited by 221 · see citing works

SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses

Koutsakos, M., Reynaldi, A., Lee, W. S., Nguyen, J. T., Amarasena, T. H., Taiaroa, G., Kinsella, P. M., Liew, K. C., Tran, T., Kent, H. E., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.017 · Cited by 106 · see citing works

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S. J., Davenport, M. P., & Cromer, D. (2023) · Nature Medicine · doi:10.1038/s41591-023-02228-4 · Cited by 102 · see citing works

Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Painter, M. M., Johnston, T. S., Lundgreen, K. A., Santos, J. J. S., Qin, J. S., Goel, R. R., Apostolidis, S. A., Mathew, D., Fulmer, B., Williams, J. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01613-y · Cited by 106 · see citing works

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant

Khan, K., Lustig, G., Roemer, C., Reedoy, K., Jule, Z., Karim, F., Ganga, Y., Bernstein, M. P., Baig, Z., Jackson, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43703-3 · Cited by 93 · see citing works

Monoclonal antibody levels and protection from COVID-19

Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40204-1 · Cited by 61 · see citing works

Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination

Fumagalli, V., Ravà, M., Marotta, D., Lucia, P. D., Bono, E., Giustini, L., Leo, F. D., Casalgrandi, M., Monteleone, E., Mouro, V., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01787-z · Cited by 51 · see citing works

Study of the mechanism by which Bacillus subtilis improves the soil bacterial community environment in severely saline-alkali cotton fields

Xia, H., Liu, H., Gong, P., Li, P., Xu, Q., Zhang, Q., Sun, M., Meng, Q., Ye, F., & Yin, W. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.178000 · Cited by 44 · see citing works

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Benkeser, D. C., Fong, Y., Janes, H., Kelly, E. J., Hirsch, I., Sproule, S., Stanley, A. M., Maaske, J., Villafana, T. L., Houchens, C. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00630-0 · Cited by 41 · see citing works

Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers

Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 43 · see citing works

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36 · see citing works

Case fatality rates of COVID‐19 during epidemic periods of variants of concern: A meta-analysis by continents

Xia, Q., Yang, Y., Wang, F., Huang, Z., Qiu, W., & Mao, A. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.01.017 · Cited by 38 · see citing works

Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO)

Mikolajczyk, R., Diexer, S., Klee, B., Pfrommer, L. R., Purschke, O., Fricke, J., Ahnert, P., Gabrysch, S., Gottschick, C., Bohn, B., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106206 · Cited by 24 · see citing works

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Carpp, L. N., Hyrien, O., Fong, Y., Benkeser, D. C., Roels, S., Stieh, D. J., Dromme, I. V., Roey, G. A. V., Kenny, A., Huang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53727-y · Cited by 24 · see citing works

Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand

Vattiato, G., Lustig, A. G., Maclaren, O. J., & Plank, M. J. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100657 · Cited by 24 · see citing works

Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes

Xie, J., Mothe, B., Alcalde‐Herraiz, M., Li, C., Xu, Y., Jödicke, A. M., Gao, Y., Wang, Y., Feng, S., Wei, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48339-5 · Cited by 23 · see citing works

COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint

Zaeck, L. M., GeurtsvanKessel, C. H., & de Vries, R. D. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00140-6 · Cited by 22 · see citing works

Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19

Zhang, F.-M., Huang, T., Wang, F., Zhang, G.-S., Liu, D., Dai, J., Zhang, J., Li, Q., Lin, G., Gao, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115721 · Cited by 21 · see citing works

SARS-CoV-2 infection rates and associated risk factors in healthcare workers: systematic review and meta-analysis

Bansal, A., Trieu, M.-C., Eriksson, E. M., Zhou, F., McVernon, J., Brokstad, K. A., & Cox, R. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-89472-5 · Cited by 20 · see citing works

Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection

Liu, C., Tsang, T. K., Sullivan, S. G., Cowling, B. J., & Yang, B. (2025) · Nature Communications · doi:10.1038/s41467-025-60024-9 · Cited by 19 · see citing works

Inference of epidemic dynamics in the COVID-19 era and beyond

Cori, A., & Kucharski, A. J. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100784 · Cited by 17 · see citing works

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Zaeck, L. M., Tan, N. H., Rietdijk, W. J. R., Geers, D., Sablerolles, R. S. G., Bogers, S., van Dijk, L. L. A., Gommers, L., van Leeuwen, L. P. M., Rugebregt, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48414-x · Cited by 18 · see citing works

Deaths averted by vaccination due to reduced transmission can exceed those from direct protection of vaccinated individuals for SARS-CoV-2Preprint

Gardner, B. J., & Kilpatrick, A. M. (2021) · medRxiv · doi:10.1101/2021.10.25.21265500 · Cited by 18 · see citing works

Applying bio-organic fertilizer improved saline alkaline soil properties and cotton yield in Xinjiang

Xia, H., Liu, H., Gong, P., Li, P., Xu, Q., Zhang, Q., Yang, C., & Meng, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-97776-9 · Cited by 16 · see citing works

Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023

Plumb, I. D., Hagen, M. B., Wiegand, R. E., Dumyati, G. K., Myers, C., Harland, K. K., Krishnadasan, A., James-Gist, J., Abedi, G. R., Fleming-Dutra, K. E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.072 · Cited by 16 · see citing works

Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts

Marrone, G., Covino, M., Merra, G., Piccioni, A., Amodeo, A., Novelli, A., Murri, R., Pompili, M., Gasbarrini, A., & Franceschi, F. (2023) · Liver International · doi:10.1111/liv.15736 · Cited by 15 · see citing works

Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates

Cromer, D., Reynaldi, A., Mitchell, A., Schlub, T. E., Juno, J. A., Wheatley, A. K., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2024) · Nature Communications · doi:10.1038/s41467-024-52194-9 · Cited by 15 · see citing works

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection

Wang, F., Huang, B., Deng, Y., Zhang, S., Liu, X., Wang, L., Liu, Q., Zhao, L., Tang, L., Wang, W., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02942-3 · Cited by 14 · see citing works

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Kumar, A., Tripathi, P., Kumar, P., Shekhar, R., & Pathak, R. (2024) · Vaccines · doi:10.3390/vaccines12050459 · Cited by 15 · see citing works

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

Zhang, B., Fong, Y., Fintzi, J., Chu, E., Janes, H., Kenny, A., Carone, M., Benkeser, D. C., van der Laan, L. W. P., Deng, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52348-9 · Cited by 14 · see citing works

Modelling the impact of the Omicron BA.5 subvariant in New Zealand

Lustig, A. G., Vattiato, G., Maclaren, O. J., Watson, L. M., Datta, S., & Plank, M. J. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0698 · Cited by 14 · see citing works

A unique cytotoxic CD4 + T cell‐signature defines critical COVID‐19

Baird, S., Ashley, C. L., Marsh‐Wakefield, F., Alca, S., Ashhurst, T. M., Ferguson, A. L., Lukeman, H., Counoupas, C., Post, J. J., Koneçny, P., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1463 · Cited by 13 · see citing works

The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study

Datta, S., Vattiato, G., Maclaren, O. J., Hua, N., Sporle, A. A., & Plank, M. J. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.101 · Cited by 14 · see citing works

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Magaret, C. A., Li, L., deCamp, A. C., Rolland, M., Juraska, M., Williamson, B. D., Ludwig, J., Molitor, C., Benkeser, D. C., Luedtke, A. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46536-w · Cited by 13 · see citing works

Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India

Gunale, B., Kapse, D., Kar, S., Bavdekar, A., Kohli, S., Lalwani, S. K., Meshram, S., Raut, A. V., Kulkarni, P., Samuel, C., et al. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.2552 · Cited by 12 · see citing works

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

D’Souza, M., Keeshan, A., Gravel, C. A., Langlois, M., & Cooper, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-01022-8 · Cited by 11 · see citing works

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial

Hertoghs, N., Roels, S., Brückner, M., SADOFF, J. C., Banbury, B. L., Akers, N. K., Howie, B., Robins, H. S., Roey, G. A. V., Tolboom, J. T. B. M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105809 · Cited by 14 · see citing works

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial

Hejazi, N. S., Shen, X., Carpp, L. N., Benkeser, D. C., Follmann, D. A., Janes, H., Baden, L. R., Sahly, H. M. E., Deng, W., Zhou, H., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.012 · Cited by 11 · see citing works

The Asymptomatic Proportion of SARS‐CoV‐2 Omicron Variant Infections in Households: A Systematic Review

Shi, N. D. J., Marcato, A. J., Spirkoska, V., Meagher, N., Villanueva‐Cabezas, J. P., & Price, D. J. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13348 · Cited by 10 · see citing works

Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”

Krammer, F., Katz, J. M., Engelhardt, O. G., Post, D. J., Roberts, P. C., Sullivan, S. G., Tompkins, S. M., Chiu, C., Schultz‐Cherry, S., & Cox, R. J. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13314 · Cited by 10 · see citing works

Individual variation in vaccine immune response can produce bimodal distributions of protection

Zachreson, C., Tobin, R. J., Szanyi, J., Walker, C., Cromer, D., Shearer, F. M., Conway, E. J., RYAN, G. E., Cheng, A., McCaw, J. M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.025 · Cited by 9 · see citing works

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

Muangnoicharoen, S., Wiangcharoen, R., Nanthapisal, S., Kamolratanakul, S., Lawpoolsri, S., Jongkaewwattana, A., Thitithanyanont, A., Luvira, V., Chinwangso, P., Thanthamnu, N., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.043 · Cited by 9 · see citing works

Modelling the impact of hybrid immunity on future COVID-19 epidemic waves

Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Müeller, I., Walker, C. R., & Baker, C. M. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09282-4 · Cited by 9 · see citing works

An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity

Counoupas, C., Chan, E., Pino, P., Armitano, J., Johansen, M. D., Smith, L. J., Ashley, C. L., Estapé, E., Troyon, J., Alca, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01144-7 · Cited by 8 · see citing works

High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection

Kawasuji, H., Morinaga, Y., Nagaoka, K., Tani, H., Yoshida, Y., Yamada, H., Takegoshi, Y., Kaneda, M., Murai, Y., Kimoto, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1377014 · Cited by 8 · see citing works

Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program

van Leeuwen, L. P. M., Grobben, M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., van Gils, M. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390022 · Cited by 8 · see citing works

Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity

Belik, M., Reinholm, A., Kolehmainen, P., Heroum, J., Maljanen, S., Altan, E., Österlund, P., Laine, L. M., Ritvos, O., Pasternack, A. H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494432 · Cited by 8 · see citing works

Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodiesPreprint

Painter, M. M., Johnston, T. S., Lundgreen, K. A., Santos, J. J. D. S., Qin, J. S., Goel, R. R., Apostolidis, S. A., Mathew, D., Fulmer, B., Williams, J. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.05.527215 · Cited by 7 · see citing works

Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection

Wagstaffe, H. R., Thwaites, R. S., Sidhu, J. K., Lindeboom, R. G. H., Kretschmer, L., Worlock, K. B., Dratva, L. M., Huang, A., Ascough, S., Papargyris, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67017-8 · Cited by 6 · see citing works

Identification of highly conserved surface-exposed peptides of spike protein for multiepitope vaccine design against emerging omicron variants: An immunoinformatic approach

Khan, M. S., Shakya, M., Verma, C. K., & Mukherjee, R. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111117 · Cited by 6 · see citing works

Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody

Chang, Y.-H., Hsu, M., Chen, W.-N., Wu, M., Kong, W., Lu, M. J., Huang, C.-H., Chang, F.-J., Chang, L., Tsai, H.-Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179726 · Cited by 5 · see citing works

Effects of individual variation and seasonal vaccination on disease risks

Hart, W. S., Amin, J., Park, H., Kitagawa, K., Jeong, Y. D., Kaye, A. R., Iwami, S., & Thompson, R. N. (2025) · Nature Communications · doi:10.1038/s41467-025-63375-5 · Cited by 5 · see citing works

SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine

Liao, B., Platen, L., Grommes, M., Cheng, C., Holzmann‐Littig, C., Christa, C., Haller, B., Kappler, V., Bester, R., Werz, M. L., et al. (2024) · Vaccines · doi:10.3390/vaccines12030308 · Cited by 5 · see citing works

Comparison of Humoral Response between Third and Fourth Doses of COVID-19 Vaccine in Hemodialysis Patients

Joo, Y., Kim, D. K., Jeon, Y. G., Kim, A., Do, H. N., Yoon, S., Kim, J. S., Jung, S. W., Hwang, H. S., Moon, J.-Y., et al. (2023) · Vaccines · doi:10.3390/vaccines11101584 · Cited by 5 · see citing works

Regional geographies and public health lessons of the COVID-19 pandemic in the Arctic

Tiwari, S., Petrov, A. N., Golosov, N., Devlin, M. K., Mark, W., DeGroote, J. P., Degai, T. S., & Ksenofontov, S. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1324105 · Cited by 6 · see citing works

Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine

Kohli, M. A., Maschio, M., Lee, A., & Igarashi, A. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.093 · Cited by 5 · see citing works

Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection

Park, H., Nakamura, N., Miyamoto, S., Sato, Y., Kim, K. S., Kitagawa, K., Kobashi, Y., Tani, Y., Shimazu, Y., Zhao, T., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv4214 · Cited by 4 · see citing works

Enabling the evaluation of COVID-19 vaccines with correlates of protection

Marchant, A., Damme, P. V., Plotkin, S. A., Neels, P., Cassetti, M. C., Cramer, J. P., Gruber, M. F., Goldblatt, D., King, D., Hartig-Merkel, W., et al. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101723 · Cited by 6 · see citing works

Australia’s COVID-19 vaccine journey: progress and future perspectives

Triccas, J. A., & Steain, M. C. (2024) · Microbiology Australia · doi:10.1071/ma24009 · Cited by 4 · see citing works

Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants

Ashley, C. L., Bloul, M., Alca, S., Smith, L., Jin, W., Khoury, D. S., Counoupas, C., Davenport, M. P., Triccas, J. A., & Steain, M. C. (2024) · Journal of Virological Methods · doi:10.1016/j.jviromet.2024.115073 · Cited by 4 · see citing works

Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection

Lee, J. E., Jin, K. N., Hong, H., Jeong, Y. J., & Yoon, S. H. (2024) · Radiology · doi:10.1148/radiol.231928 · Cited by 4 · see citing works

The Effectiveness of the Third Dose of COVID-19 Vaccine: When Should It Be Performed?

Biganzoli, G., Mendola, M., Perrone, P. M., Antonangeli, L. M., Longo, A. B. E., Carrer, P., Colosio, C., Consonni, D., Marano, G., Boracchi, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12030315 · Cited by 4 · see citing works

Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment

Augello, M., Wagenhäuser, I., Krone, M., Dauby, N., Ferrara, P., Sabbatucci, M., Ruță, S. M., Rezahosseini, O., Velikov, P., Gkrania‐Klotsas, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126184 · Cited by 4 · see citing works

Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea

Moon, S. Y., Son, M., Kang, Y. W., Koh, M., Lee, J. Y., & Baek, Y. H. (2024) · Virology Journal · doi:10.1186/s12985-024-02464-1 · Cited by 3 · see citing works

Impact of pre-Omicron COVID-19 vaccine boosters on the risk of Omicron variant infections: A systematic review and meta-regression

Pan, B.-Y., Tseng, I., Feng, Y. A., & Fang, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.04.002 · Cited by 3 · see citing works

Clinical characteristics, SARS-CoV-2 variants, and outcomes of adults hospitalized due to COVID-19 in Latin American countries

López-Macías, C. I. R., López-Medina, E., Alves, M. B., Matos, A. D. R., Hernández-Villena, J. V., Torres, Z. A., Sarabia, L. E., Manrique-Ramirez, P., Tejado-Gallegos, L. F., Ramirez, L., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100648 · Cited by 3 · see citing works

The Mirror of Erised: a retrospective population-wide study of Czech all-cause mortality data by COVID-19 vaccination status

Vencálek, O., Fürst, T., Princova, E., & Fürstová, J. (2025) · BMC Public Health · doi:10.1186/s12889-025-23619-x · Cited by 3 · see citing works

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

Mkhize, N. N., Zhang, B., Brackett, C., Elyanu, P., Tapley, A., Dadabhai, S. S., Hu, J., Do, B. T. N., Schuster, D. J., Heptinstall, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63948-4 · Cited by 3 · see citing works

Antibody Titers and the Risk of Infection During the SARS-CoV-2 Omicron Phase in Bizen City, Japan

Kadowaki, T., Sasaki, A., Matsumoto, N., Mitsuhashi, T., Hagiya, H., Takao, S., & Yorifuji, T. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae207 · Cited by 3 · see citing works

Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Preprint

Ramirez, S. I., Lopez, P. G., Faraji, F., Parikh, U. M., Heaps, A., Ritz, J., Moser, C., Eron, J. J., Wohl, D. A., Currier, J. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.25.564014 · Cited by 3 · see citing works

Clinical and Economic impact of updated Fall 2023 COVID-19 vaccines in the Immunocompromised Population in CanadaPreprint

Lee, A. S., Jayasundara, K., Kohli, M. A., Maschio, M., Fust, K., Joshi, K., de Velde, N. V., & Beck, E. C. (2023) · medRxiv · doi:10.1101/2023.11.10.23298369 · Cited by 3 · see citing works

T cell-mediated protection in absence of virus neutralizing antibodies

Alpizar, Y. A., & Dallmeier, K. (2025) · Nature Microbiology · doi:10.1038/s41564-024-01921-5 · Cited by 2 · see citing works

Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice

Fibriani, A., Yamahoki, N., Shani, A. M., Rofiqoh, A., Siregar, A. L. F., Gunawan, C., Mayorga, C. G. D., Tjia, T. O. S., Nugrahapraja, H., Giri-Rachman, E. A., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100632 · Cited by 2 · see citing works

Putting computational models of immunity to the test—An invited challenge to predict B.pertussis vaccination responses

Shinde, P. S., Willemsen, L., Anderson, M., Aoki, M., Basu, S., Burel, J. G., Cheng, P., Dastidar, S. G., Dunleavy, A., Einav, T., et al. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012927 · Cited by 2 · see citing works

Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine

Vergori, A., Matusali, G., Cimini, E., Cozzi‐Lepri, A., Mazzotta, V., Mariotti, D., Colavita, F., Gili, S., Cristofanelli, F., Fusto, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083521 · Cited by 2 · see citing works

Impact of vaccination on SARS-CoV-2 infections and long COVID symptoms: a cross-sectional study in China

Yan, X., Zhao, X., Wang, H. B., Du, Y., Liu, L., Liu, J., Wang, Q., & Wei, S. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11677-w · Cited by 2 · see citing works

Modelling the interaction between ethnicity and infectious disease transmission dynamics in Aotearoa New Zealand during the first Omicron wave of the COVID-19 pandemic

Lomas, V. X., Chambers, T. J., & Plank, M. J. (2025) · Mathematics in Medical and Life Sciences · doi:10.1080/29937574.2025.2591407 · Cited by 2 · see citing works

COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

Sullivan, D. J., Reik, R., Prichard, A. B., Pagan, M., Tobian, A. A. R., Caturegli, P., Pekosz, A. S., Klein, S. L., Bloch, E. M., Shoham, S., et al. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2623136 · Cited by 2 · see citing works

Immune responses associated with protection from SARS-CoV-2 infection

Reynaldi, A., Lee, W. S., Selva, K. J., Audsley, J., Trieu, M.-C., Chung, A. W., Cromer, D., Tan, H., Wheatley, A. K., Juno, J. A., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128579 · Cited by 2 · see citing works

An optimal control model with contact restrictions applied to COVID-19 pandemic

Lv, W., & Xu, M. (2024) · Journal of Industrial and Management Optimization · doi:10.3934/jimo.2024068 · Cited by 2 · see citing works

Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan

Matsumoto, N., Sasaki, A., Kadowaki, T., Mitsuhashi, T., Takao, S., & Yorifuji, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126156 · Cited by 2 · see citing works

Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used

Göbel, C., Heinze, A., Heinze-Kuhn, K., Karstedt, S., Morscheck, M., Tashiro, L., Cirkel, A., Hamid, Q., Halwani, R., Temsah, M., et al. (2025) · Vaccines · doi:10.3390/vaccines13020113 · Cited by 1 · see citing works

A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity

Ana‐Sosa‐Batiz, F., Verma, S. K., Shafee, N., Miller, R., Conner, C., Hastie, K. M., Timis, J., Maule, E., Nguyen, M. N., Tran, L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105619 · Cited by 2 · see citing works

Estimated US Trends in SARS-CoV-2 Spike Antibody Concentrations and Correlation to Risk of First-Time Infections Based on Blood Donations, 2022

Jones, J. M., Grebe, E., Lartey, I., Stone, M., Spencer, B. R., Akinseye, A., Manrique, I. M., Fink, R. V., Green, V., Saá, P., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf329 · Cited by 2 · see citing works

Modelling the impact of hybrid immunity on future COVID-19 epidemic wavesPreprint

Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Müeller, I., Walker, C. R., & Baker, C. M. (2023) · medRxiv · doi:10.1101/2023.03.12.23287174 · Cited by 2 · see citing works

Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppressionPreprint

Karim, F., Bernstein, M. P., Jule, Z., Lustig, G., Upton, J., Ganga, Y., Khan, K., Reedoy, K., Mazibuko, M., Govender, K., et al. (2023) · medRxiv · doi:10.1101/2023.08.18.23293746 · Cited by 2 · see citing works

Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination

Schest, S., Langer, C., Stiegler, Y., Karnuth, B., Arends, J. P., Stiegler, H., Masetto, T., Peter, C., & Grimmler, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257265 · Cited by 1 · see citing works

Predictors of Long COVID Among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy

Sun, X., Fusco, M. D., Lupton, L. L., Yehoshua, A., Alvarez, M. B., Allen, K. E., Puzniak, L., Lopez, S. M. C., & Cappelleri, J. C. (2024) · Healthcare · doi:10.3390/healthcare12232321 · Cited by 1 · see citing works

Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population

Jacobs, M. B., Clark, A. E., Goldhaber, N. H., Valentine, H. D., Rivera, A., Ngo, T., Barber, T., Holmes, J., Manfredi, B., Garretson, A. F., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae622 · Cited by 2 · see citing works

Personalized prediction of SARS-CoV-2 vaccine-induced immunity after boost: a longitudinal analysis using joint modeling

Papadopoulos, I., Diep, A. N., Schyns, J., Gourzonès, C., Minner, F., Bonhomme, G., Paridans, M., Gillain, N., Husson, E., Garigliany, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619631 · Cited by 1 · see citing works

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination

Purcell, R. A., Koutsakos, M., Kedzierski, Ł., Allen, L. F., Williams, O., Wang, J.-W. D., Cavic, G., Wheatley, A. K., Lee, W. S., Wines, B. D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01268-w · Cited by 4 · see citing works

Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms

Saito, T., Couzinet, A., Suzuki, T., Shimomura, M., Ryo, A., Miyakawa, K., Katayama, Y., & Nakatsura, T. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127942 · Cited by 1 · see citing works

Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2

Mahanty, S., Eriksson, E. M., Edler, P., Mordant, F. L., Kiernan‐Walker, N., Price, D. J., Braat, S., Conway, E. J., Bryant, V. L., Ding, H., et al. (2025) · mBio · doi:10.1128/mbio.03221-25 · Cited by 1 · see citing works

Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents

Breznik, J. A., Ang, J. C., Bhakta, H., Liu, L.-M., Bilaver, L., Kennedy, A. E., Cowbrough, B., Rahim, A., Clare, R., Bramson, J. L., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128160 · Cited by 1 · see citing works

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial

Spehner, L., Orillard, É., Falcoz, A., Lepiller, Q., Bouard, A., Almotlak, H., Kim, S. C. H., Curtit, E., Meynard, G., Jary, M., et al. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000054 · Cited by 1 · see citing works

Design, synthesis, and biological evaluation of novel 2′-deoxy-2′-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents

Gao, M., Zhang, Z., Yao, G., Zhang, L., Duan, A., Zhang, Y., Wang, Y., Zhao, J., & Zhang, J. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.106060 · Cited by 1 · see citing works

SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography

Ma, J., Kaniper, S., Vabishchevich, Y., Nyantakyi, N., Lynch, D., Chun, F., Dai, H., & Gerhard, G. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-90730-9 · Cited by 1 · see citing works

Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women

Lupton, D. A., Whitten, T., Tay, A. K., Beek, K., Green, M. J., Hassoun, F., Moussa, B., Silove, D. M., & Rees, S. J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127251 · Cited by 1 · see citing works

National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis

Klaassen, F., Swartwood, N. A., Chitwood, M. H., Lopes, R., Haraguchi, M., Salomon, J. A., Cohen, T., & Menzies, N. A. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf532 · Cited by 1 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection

Liu, C., Tsang, T. K., Sullivan, S. G., Cowling, B. J., & Yang, B. (2025) · Nature Communications · doi:10.1038/s41467-025-60024-9 · Cited by 19 · see citing works

Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers

Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 43 · see citing works

Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis

Elias, K. M., Mitchell, A., Stadler, E., Schlub, T. E., Khan, S. R., Xue, C., Kent, S. J., Cromer, D., Davenport, M. P., & Khoury, D. S. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005230